MCRB Seres Therapeutics Inc.

$9.67 +1.68%

225,868 Shares Traded
135,610 Average Volume (last 30 days)

as of February 22, 2018 EST IEX Real-Time Price

Short Pain Metrics

Approximate Amount of Money Shorts Have Lost on the Day: $872.57 thousand
If Intiated on the First, Shorts Have Realized a Year to Date Return of:9.86%
If Intiated One Month Ago, Shorts Have Realized a Return of:12.03%
If Initiated Five Days ago, Shorts Have Realized a Return of:-7.22%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bearish
50 Day Moving Average Indicator Bearish
52 Week High/Low Indicator Neutral

Short Stats

Short Percent to Float 13.7%
Short Interest5.45 million
Float39.8 million
Short Ratio41.14
Market Cap$385.44 million
Market Maker ActivityDaily Short Volume


Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer (Business Wire)
Seres presents pipeline update at JPM18; shares ahead 2% (SeekingAlpha)
Seres (MCRB) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow (SeekingAlpha)
Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference (Business Wire)
Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis (Business Wire)
Seres Therapeutics' SER-287 an Orphan Drug in U.S. for UC (SeekingAlpha)
Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis (Business Wire)
Seres teams up with MD Anderson and Parker Institute to evaluate microbiome therapies in cancer (SeekingAlpha)
Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed(TM) Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team (PR Newswire)
Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology (Business Wire)

Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 73.3%

Earnings Stats

PE Ratio -4.56
Dividend Yield 0%
Peer EarningsEarnings Calendar


200 Day Moving Average $11.29
50 Day Moving Average $10.02
52 Week High $17.42
52 Week Low $7.9

Data provided for free by IEX. Questions? Read the FAQ